MedTrace Logo

Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients

NCT01559103 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2021-02-09

No results posted yet for this study

Summary

Study to assess the safety and tolerability of MEDI5117 in Rheumatoid Arthritis patients

Conditions

Interventions

BIOLOGICAL

MEDI5117

Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg

BIOLOGICAL

MEDI5117 Placebo

Intravenous infusion administered over 60 minutes

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United States
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01559103 on ClinicalTrials.gov